Filing Flows › Atrium Therapeutics (RNA) › Q2 2026 › vs Q2 2025
Atrium Therapeutics (RNA) Q2 2026 vs Q2 2025 (year over year)
Atrium Therapeutics's revenue fell $843K (-22%) from $3.8M in Q2 2025 to $3.0M in Q2 2026.
Atrium Therapeutics, Q2 2026: revenue $3.0M (-22% year over year), operating margin -752.9%, net loss $20.2M, operating cash flow −$3.9M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $3.0M | $3.8M | −$843K | -22% |
| Other income, net | $2.4M | −$15K | $2.4M | — |
| Net loss | $20.2M | $12.9M | $7.3M | +57% |
| Costs & expenses | $25.6M | $16.7M | $8.9M | +53% |
| Operating costs | $25.6M | $16.7M | $8.9M | +53% |
| Research & development | $15.3M | $13.3M | $2.0M | +15% |
| General & admin | $10.3M | $3.4M | $6.9M | +201% |
| Operating cash sources | $20.2M | $12.9M | $7.3M | +57% |
| Depreciation | $343K | $79K | $264K | +334% |
| Share-based compensation | $893K | $1.7M | −$807K | -47% |
| Working capital & other | $15.0M | −$807K | $15.8M | — |
| Cash used in operations | $3.9M | $11.9M | −$8.0M | -67% |
| Net loss absorbed | $20.2M | $12.9M | $7.3M | +57% |
Questions
How much did Atrium Therapeutics's revenue grow year over year in Q2 2026?
Atrium Therapeutics's revenue fell $843K (-22%) from $3.8M in Q2 2025 to $3.0M in Q2 2026.